Article

Accelerated First-in-Human Clinical Trial of EIDD-2801/MK-4482 (molnupiravir), a Ribonucleoside Analogue with Potent Antiviral Activity Against SARS-CoV-2

2021-05-14

Abstract excerpt

<title>Abstract</title> <p>A recently published article described the safety, tolerability and pharmacokinetic profile of molnupiravir, a novel antiviral agent with potent activity against SARS-CoV-2, the causative agent of COVID-19. Here, we report an unprecedented collaboration between sponsor, contract research organization (CRO) and regulatory authorities that enabled accelerated generation of these phase I d...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 9ed30f0b-4002-50d5-8a55-54e9fcd7ff2f
DOI: 10.21203/rs.3.rs-477300/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Accelerated First-in-Human Clinical Trial of EIDD-2801/MK-4482 (molnupiravir), a Ribonucleoside Analogue with Potent Antiviral Activity Against SARS-CoV-2DOI 10.21203/rs.3.rs-477300/v1Read

Design and implementation of an international, multi-arm, multi-stage platform master protocol for trials of novel SARS-CoV-2 antiviral agents: Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3)Semantic proximity Read

A Randomised -Controlled Phase 2 trial of Molnupiravir in Unvaccinated and Vaccinated Individuals with Early SARS-CoV-2Semantic proximity Read

Molnupiravir: A Versatile Prodrug against SARS-CoV-2 VariantsSemantic proximity Read

Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus-M <sup>Pro</sup> inhibitors with potent in vivo efficacySemantic proximity Read

Considering mutational meltdown as a potential SARS-CoV-2 treatment strategy.Semantic proximity Read

Navigating the COVID-19 Therapeutic Landscape: Unveiling Novel Perspectives on FDA-Approved Medications, Vaccination Targets, and Emerging Novel StrategiesSemantic proximity Read

Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral ActivitySemantic proximity Read

Molnupiravir, an Oral Antiviral Treatment for COVID-19Semantic proximity Read

The IDentif.AI 2.0 Pandemic Readiness Platform: Rapid Prioritization of Optimized COVID-19 Combination Therapy RegimensSemantic proximity Read

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.Semantic proximity Read

From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infectionSemantic proximity Read

An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 and multiple endemic, epidemic and bat coronavirusSemantic proximity Read